Input: [0] 2E [Promotion] Weigh yourself daily at the same time and on the same scale. This is important. Checking on your progress will help you control your weight. [Prevention]

Output: Check your progress and prevent failure. Weigh yourself daily at the same time and on the same scale. This will help you control your weight.


Input: [0] 3M [Promotion] Exercise regularly. Exercise will maintain a healthy weight, blood pressure, and reduce problems with diabetes. [Prevention]

Output: Prevent diabetes problems, weight gain, and worsening blood pressure. Not exercising affects the body’s ability to handle blood sugar.


Input: [0] 4N [Promotion] Sustain your weight loss. Use the “plate method”. Fill up ½ your plate with vegetables, ¼ with starch, ¼ with protein. [Prevention]

Output: Avoid eating too many calories. Use the “plate method”. Fill up ½ your plate with vegetables, ¼ with starch, ¼ with protein.


Input: [0] 5E [Promotion] Check your food intake. Record everything you eat and portion sizes. Checking increases awareness of what you are eating. [Prevention]

Output: Check your food intake. Avoid falling into the trap of checking only “good days”. Record everything you eat and portion sizes.


Input: [0] 6M [Promotion] Count steps to increase the amount you walk. Use your pedometer. Set a goal of adding 150 steps a day up to 5000 steps a day or 2.5 miles. [Prevention]

Output: Don’t risk falling off the exercise bandwagon. Count your steps to increase the amount you walk up to 5000 steps a day or 2.5 miles.


Input: [0] 7N [Promotion] Use smaller plates. You will still clean your plate, feel satisfied, and have better portion control. [Prevention]

Output: Prevent over eating. Use smaller plates to avoid filling a larger plate with extra calories.


Input: [0] 8E [Promotion] Keep track of the things that lead to unplanned and overeating. [Prevention]

Output: Prevent yourself from unplanned eating. Keep track of the things that lead to unplanned and overeating.


Input: [0] 9M [Promotion] Activity burns calories and helps maintain weight. Climbing stairs, parking further away, or walking to the office add up quickly to 30 min a day. [Prevention]

Output: Don’t let exercise slip away. Small activities such as climbing stairs, parking further away, or walking to the office add up quickly to 30 min a day.


Input: [0] 10N [Promotion] Eat slowly. Put fork down between bites. Check fullness level during meal. When full push your plate away. Satisfaction takes 15-20 min. [Prevention]

Output: Avoid feeling full and giving in to cravings. Eat slowly. Put fork down between bites. Check fullness level. Satisfaction takes 15-20 min.


Input: [0] 11M [Promotion] Keep exercising! After 1 year, dieters who exercise maintain most of their original weight loss. [Prevention]

Output: Steer clear of gaining weight back. Dieters who do not exercise maintain only half of their original weight loss.


Input: [0] 12N [Promotion] Select healthy breakfast cereals. Follow the “5 and 5” rule—5 grams fiber & 5 or less of sugar. Or try heart-healthy oatmeal with honey! [Prevention]

Output: Steer clear of high sugar breakfast cereals. Follow the “5 and 5 rule” —5 grams of fiber and 5 or less grams of sugar.


Input: [0] 13E [Promotion] Monitor your progress and how you are doing. Schedule time to review your progress in your calendar. [Prevention]

Output: Remember not to forget to monitor your progress. Schedule time to review your progress in your calendar.


Input: [0] 14M [Promotion] Exercise helps more than just with weight loss. It helps to decrease high blood pressure, improve diabetes, and decrease cholesterol. [Prevention]

Output: Exercise helps more than just with weight loss. It helps to prevent cancer, diabetes, high blood pressure, and gaining weight back.


Input: [0] 15N [Promotion] Reward yourself. It’s OK to have a little sweet foods such as pie, cookies, and candy, and alcohol. [Prevention]

Output: Prevent yourself from overindulging. It’s OK to have a little sweet foods such as pie, cookies, and candy, and alcohol.


Input: [0] 16M [Promotion] Cross train. Vary your exercise: walk, bike, elliptical, water /chair aerobics. It will help you stay motivated and have fun! [Prevention]

Output: Prevent boredom, injury, and over training with your exercise. Cross train: walk, bike, elliptical, water/chair aerobics.


Input: [0] 17N [Promotion] Identify and change habits and foods that lead to binges including risky foods kept in the house such as chips or watching TV while eating. [Prevention]

Output: Avoid being tempted by foods and habits that lead to binges. Don’t keep risky foods in the house such as chips or watch TV while eating.


Input: [0] 18E [Promotion] Stay on top of how you are doing. Review your monitoring forms to check for patterns. Monitor at least 2-3 times a week. [Prevention]

Output: Prevent yourself from slipping. Pick 2-3 days to monitor and every so often review your monitoring forms to check for patterns.


Input: [0] 19M [Promotion] For general fitness: exercise 30 minutes daily. 8-10 exercises, 8-15 repetitions, 1-3 sets, 30-90 second rest between sets. [Prevention]

Output: Don't exercise too little and stop all together: exercise 30 minutes daily. 8-10 exercises, 8-15 repetitions, 1-3 sets, 30-90 second rest between sets.


Input: [0] 20N [Promotion] Use a grocery list for grocery shopping and only buy planned for items. This will help you buy good healthy foods. [Prevention]

Output: Prevent temptation to buy unhealthy foods. Avoid meal planning or shopping for groceries when you are hungry.


Input: [0] 21E [Promotion] Limit size of portions at mealtimes by measuring planned servings. Keep measuring utensils readily available. [Prevention]

Output: Don’t let portion sizes increase in size. Keep measuring utensils readily available and measure planned servings at mealtimes.


Input: [0] 22E [Promotion] Weigh yourself daily. Place the weight on a graph to see trends over time. It is natural to fluctuate daily due to things such as water. [Prevention]

Output: Don’t feel surprised and upset when daily weighing. Place the weight on a graph to see trends over time. It is natural to fluctuate daily.


Input: [0] 23N [Promotion] Plan meals in advance to increase self-awareness—3 meals and up to 2 snacks per day going no longer than 4-5 hours between eating. [Prevention]

Output: Plan meals in advance to avoid overeating and being tempted to select poor foods —3 meals, 2 snacks/day no more than 4-5 hrs between eating.


Input: [0] 24E [Promotion] Be aware of your blood pressure and monitor it. Check it when and where you can: at home, the doctor’s office, blood pressure machine at the drug store, etc. [Prevention]

Output: Prevent or reduce high blood pressure. Keep track of your blood pressure at home, the doctor’s office, machine at the drug store, etc.


Input: [0] 25M [Promotion] Stay motivated! At the beginning of the week plan your exercise sessions and treat them like you would any other appointment. [Prevention]

Output: Prevent becoming demotivated. At the start of the week plan exercise sessions and treat them like any other appointment.


Input: [0] 26E [Promotion] Monitor your blood sugar as prescribed and HbA1c every 3-6 months. Keep track of fluctuations and where they are to see how much they are. [Prevention]

Output: Avoid large fluctuations in your blood sugar. Monitor your blood sugar as prescribed and HbA1c every 3-6 months.


Input: [0] 27M [Promotion] When you don’t feel like working out, bargain with yourself to exercise for just 10 minutes then see how you feel. [Prevention]

Output: Don’t fall into the slippery slope of not feeling like exercising. Contract with yourself to exercise for just 10 min then see how you feel.


Input: [0] 28N [Promotion] Make small changes. Use trade-offs such as: I will have dessert every OTHER night or, I will only eat half of the dessert. [Prevention]

Output: Avoid tempting foods. Use trade-offs such as: I will have dessert every OTHER night or, I will only eat half of the dessert.


Input: [0] 29M [Promotion] Any exercise is better than no exercise. Use a strategy to find a way to get in at least some exercise. [Prevention]

Output: Don’t slip into the “I don’t have time to exercise” today excuse. Any exercise is better than no exercise.


Input: [0] 30N [Promotion] Use restaurant strategies: 2 vegetable servings, 1 caloric beverage. If calories are listed keep meals below 800. [Prevention]

Output: Don’t be tempted to overeat when at restaurants: 2 vegetable servings, 1 caloric beverage, don’t arrive hungry. Keep meals below 800 calories.


Input: [0] Color [1] Hardness [3] Name [4] System [5] Habit [6] SG [7] Notes [2]

Output: Luster


Input: [0] White to Tan, may be Greyish [1] 2 to 2½ [3] KAOLINITE Al2Si2O5(OH)4 [4] Triclinic [5] usually as compact earthy masses [6] 2.6 [7] has an earth odor when moistened, sticks to a dry tongue [2]

Output: earthy


Input: [0] Colorless to White or Greyish-white, may be tinted other colors [1] 3 to 3½ [3] ANHYDRITE CaSO4 [4] Orthorhombic [5] usually in coarsely crystalline masses exhibiting a pseudo-cubic cleavage, or in granular masses with no cleavage apparent, crystals rare and usually equant or thick tabular [6] 2.9 to 2.98 [2]

Output: vitreous and/or pearly


Input: [0] Colorless to White or Greyish-white, may be tinted other colors [1] 3 to 3½ [3] WITHERITE (Aragonite Group): BaCO3 [4] Orthorhombic, pseudo- hexagonal [5] usually as stout prismatic twinned crystals with a hexagonal cross section, often with pyramidal terminations on both ends, more rarely as globular to botryoidal clusters, coarse fibrous aggregates, and granular [6] 4.29 [7] often hazed, will effervesce in cold acid. Has cleavage, but it may not be seen. [2]

Output: vitreous to sub-vitreous


Input: [0] Colorless to White or Grey, may be tinted other colors [1] 3½ to 4 [3] STRONTIANITE (Aragonite Group) SrCO3 [4] Orthorhombic [5] usually in granular or fibrous aggregates, may be columnar, crystals short prismatic to acicular, often pseudo-hexagonal in cross- section (Ca-rich) [6] 3.76 [7] effervesces mildly in cold acids, or not at all. Distinguished from cerussite by its notably lower specific gravity, lighter feel. Also it is not as common as cerussite. [2]

Output: vitreous to sub-vitreous, silky when fibrous


Input: [0] Shades of Green, olive, apple, dark to blackish, often mottled [1] 2½ to 4; rarely 5 to 6 in dense massive material [3] ANTIGORITE/ LIZARDITE/AMESITE (Serpentine Group) Generally (Mg,Al)3(Si,Al)2O5(OH)4 [4] Monoclinic, Orthorhombic and Triclinic [5] usually in crystalline masses, often platy or columnar [6] 2.4 to 2.79 (antigorite), 2.55 to 2.61 (lizardite), 2.71 to 2.80 (amesite) [7] These serpentine minerals are almost impossible to tell apart, particularly in massive forms. They may co-exist at the same locality. Still, information on the specific locality a specimen comes from may be the best bet for nailing down the ID. [2]

Output: sub-vitreous to greasy luster, feels greasy


Input: [0] White to Grey, Pale-green to Olive-green, Golden-yellow to Brown [1] 2 to 3 [3] CLINOCHRYSOTILE/ ORHTOCRYSOTILE/ PARACHRYSOTILE (Serpentine Group): Mg3Si2O5(OH)4 [4] Monoclinic & Orthorhombic [5] usually in fine fibrous aggregates, fibers often very long and "weaveable," [6] 2.53 to 1.55 [7] "Asbestos." is an industrial term for several long-fiber species (not all Serpentines) that can be made into cloth or mats. These species are extremely difficult to tell apart, although parachrysotile is rare and not likely to be seen. Most specimens are simply labeled with the generic term: CHRYSOTILE [2]

Output: silky


Input: [0] Orange-red to Ruby-red, Brownish-red to Brownish-yellow or pale Straw-yellow [1] 2½ to 3 [3] VANADINITE (Apatite Group): Pb5(VO4)3Cl [4] Hexagonal [5] usually in barrel- shaped prismatic hexagonal crystals, either long or short, may be acicular in clusters or mats ("endlichite"), and as hollow prisms - "hopper" crystals [6] 6.88 [7] streak white, may be yellowish [2]

Output: luster sub-vitreous to sub-resinous


Input: [0] Dark-green to Yellow-green, Yellow to Orange-Yellow, Brown, White, even Colorless [1] 3½ [3] PYROMORPHITE (Apatite Group): Pb5(PO4)3Cl [4] Hexagonal [5] usually in barrel- shaped, prismatic hexagonal crystals, may also be spindle- shaped, hollow  "hopper crystals";  rarely tabular or pyramidal, crystals may exhibit concentric color or structural zones due to zoned variations in composition [6] 7.04 [7] white streak; difficult to distinguish from mimetite without tests for PO4 vs. AsO4. [2]

Output: sub-vitreous to resinous


Input: [0] Pale-yellow to Yellowish-brown, Orange-yellow to Orange-red, White to Colorless [1] 3½ to 4 [3] MIMETITE (Apatite Group): Pb5(AsO4)3Cl [4] Hexagonal [5] usually in simple barrel-shaped prismatic crystals, rarely tabular or acicular, may be botryoidal or globular [6] 7.28 [7] Difficult to distinguish from pyromorphite without tests for AsO4 vs. PO4; Named for the fact that it closely mimics pyromorphite [2]

Output: luster sub-vitreous to resinous


Input: [0] Green to Yellow, Greenish-white, Yellowish-Brown to Brown, rarely other hues [1] 3½ to 4 [3] WAVELLITE: Al3(PO4)2(OH,F)3.5H2O [4] Orthorhombic [5] usually in radiating fibrous aggregates or stellate clusters, as crusts, may be stalactic [6] 2.36 [7] streak white; one perfect and one distinct cleavage, but they are rarely seen, dissolves in cold acids. [2]

Output: vitreous to pearly, sometimes resinous


Input: [Common Name] Field Maple [Latin Name] Acer campestre [Conditions] Small size makes it ideal for gardens [Season] Summer [Quality to wildlife]

Output: Commonly found in wild hedgerows and woodlands, it provides good cover for birds and attracts many insects


Input: [Common Name] Yarrow [Latin Name] Achillea milleflora [Conditions] Good in full sun, requires little care [Season] Provide colour in summer [Quality to wildlife]

Output: Attract insects and butterflies


Input: [Common Name] Chives [Latin Name] Allium schoenoprasum [Conditions] Open sunny situation and well-drained soil. [Season] Summer [Quality to wildlife]

Output: Attracts insects to its purple globe flowers


Input: [Common Name] Pheasant Tail Grass [Latin Name] Anemanthele Lessoniana [Conditions] Excellent all year accent plant for a sheltered sunny border [Season] Summer [Quality to wildlife]

Output: Bushy grass provides cover for insects and ground feeding birds


Input: [Common Name] Astilbe [Latin Name] Astilbe x arendsii ‘Irrlicht’ [Conditions] Shade loving [Quality to wildlife]

Output: Thick foliage and large clusters of flowers to attract insects


Input: [Common Name] Gold Dust Plant [Latin Name] Aucuba japonica ‘vaiegata’ [Conditions] Evergreen shrub [Quality to wildlife]

Output: Thick foliage to provide good cover for birds all year round.


Input: [Common Name] Weeping Birch [Latin Name] Betula pendula [Conditions] Suitable for small gardens [Quality to wildlife]

Output: Good cover for birds and insects, the seeds are eaten by many finches


Input: [Common Name] Bellflower (Telham Beauty) [Latin Name] Campanula persicifolia [Conditions] Self seeds readily tolerating even poor soils [Season] Low rosette of leaves all year round, flowers in summer [Quality to wildlife]

Output: Attracts insects with its large stalks of bell flowers all summer


Input: [Common Name] Sedge [Latin Name] Carex pendula [Conditions] Fully hardy. Evergreen tuft forming. [Quality to wildlife]

Output: Cover for birds and insects


Input: [Common Name] Hornbeam [Latin Name] Carpinus betulus [Conditions] Low lying rich soils – is shade tolerant [Quality to wildlife]

Output: Their nuts are attractive to birds


Input: [Common Name] Cornflower [Latin Name] Centaurea cyanus [Conditions] Requires sun, in any well-drained soil. [Season] Summer/Autumn [Quality to wildlife]

Output: Their flowers attract insects in the summer


Input: [Common Name] Dogwood [Latin Name] Cornus Alba [Conditions] Will tolerate variety of soils and locations. Prefers neutral to acid, moist soils with full sun to promote winter colour. [Season] June-August [Quality to wildlife]

Output: Berries taken by wide variety of birds. Winter interest.


Input: [Common Name] Cotoneaster [Latin Name] Cotoneaster x Cornuibia [Conditions] Grow in moderately well-drained soil; sun or part-shade. [Season] Evergreen [Quality to wildlife]

Output: Berries are eaten by thrushes, ring-necked parakeets, starlings, blackcaps, tree sparrows, finches and waxwings. Small compact leaves provide good nestcover. Clusters of flowers to attract insects in the summer, turning to large clusters of bright red berries in the winter


Input: [Common Name] Foxglove [Latin Name] Digitalis Purpurea [Conditions] Fully to frost hardy. Does best in semi-shade and moist but well-drained soil. [Season] Summer [Quality to wildlife]

Output: Bees


Input: [Common Name] Ferns [Latin Name] Dryopteris affinis [Conditions] Partial sun or shady conditions [Quality to wildlife]

Output: Good cover for ground feeding creatures in summer


Input: [Vitamin] Vitamin A [Synthetic Vitamin] Acetate Retinal Palmitate Beta Carotene [Food-Based Vitamin]

Output: Fish Oils Liver Carrot Powder

Vitamins: Names of Synthetic and Food-Based Vitamins - Natural Health ChiropracticVitamins: Names of Synthetic and Food-Based Vitamins - Natural Health Chiropractic


Input: [Vitamin] Vitamin B1 [Synthetic Vitamin] Thiamine HCL Thiamine Mononitrate [Food-Based Vitamin]

Output: Nutritional Yeast

Vitamins: Names of Synthetic and Food-Based Vitamins - Natural Health ChiropracticVitamins: Names of Synthetic and Food-Based Vitamins - Natural Health Chiropractic


Input: [Vitamin] Vitamin B3 [Synthetic Vitamin] Niacin [Food-Based Vitamin]

Output: Nutritional Yeast Liver

Vitamins: Names of Synthetic and Food-Based Vitamins - Natural Health ChiropracticVitamins: Names of Synthetic and Food-Based Vitamins - Natural Health Chiropractic


Input: [Vitamin] Vitamin C [Synthetic Vitamin] Ascorbic Acid Pycnogenols [Food-Based Vitamin]

Output: Green Leafy Vegetables Buckwheat juice Citrus

Vitamins: Names of Synthetic and Food-Based Vitamins - Natural Health ChiropracticVitamins: Names of Synthetic and Food-Based Vitamins - Natural Health Chiropractic


Input: [Vitamin] Vitamin D [Synthetic Vitamin] Irradiated Ergosterol [Food-Based Vitamin]

Output: Cholecalciferol

Vitamins: Names of Synthetic and Food-Based Vitamins - Natural Health ChiropracticVitamins: Names of Synthetic and Food-Based Vitamins - Natural Health Chiropractic


Input: [Vitamin] Vitamin E [Synthetic Vitamin] d-Alpha Tocopherol dl-Alpha Tocopherol d-Alpha Succinate [Food-Based Vitamin]

Output: Wheat Germ oil Green Leafy Vegetables Peavine plant

Vitamins: Names of Synthetic and Food-Based Vitamins - Natural Health ChiropracticVitamins: Names of Synthetic and Food-Based Vitamins - Natural Health Chiropractic


Input: [0] Supplement [1] Action [2]

Output: Research


Input: [0] Caffeine [1] Muscle contractility, endurance, fat metabolism [2]

Output: Supports


Input: [0] Nitric Oxide [1] Aerobic performance, lowers energy cost of exercise [2]

Output: Controversial


Input: [0] Carbohydrates [1] Time to fatigue, improve endurance performance [2]

Output: Supports


Input: [0] Energy gels [1] Quickly supply CHO during exercise [2]

Output: Supports


Input: [0] Protein [1] Optimizes muscular growth & repair [2]

Output: Supports


Input: [0] Sports drinks [1] Endurance perf., supplies CHO, electrolytes, fluid [2]

Output: Supports


Input: [0] Anti-oxidants [1] Protects against free radicals, reduce muscle damage [2]

Output: Controversial


Input: [0] Anti-inflammatories [1] Reduce muscle damage & pain [2]

Output: Supports


Input: [0] Electrolytes [1] Prevents dehydration, Na+ depletion, and fluid loss [2]

Output: Supports


Input: [Vegetation Treatment] Twenty-year old forest [Description]

Output: Any well-established forest with trees spaced about 2 m apart, about 5 m tall or taller. Ground is completely covered with a substantial layer of forest duff.

Disturbed WEPP Technical Documentation, Preliminary draft 02/00

Table 3. Vegetation treatment options in the Disturbed WEPP interface


Input: [Vegetation Treatment] Five-year old forest [Description]

Output: A vegetation that has become sufficiently well established to generate 100 percent ground cover. May be a reasonable estimate of a clear-cut forest between skid trails, where there is a considerable amount of brush, grass, or young trees remaining after harvest to maintain soil residue cover.

Disturbed WEPP Technical Documentation, Preliminary draft 02/00


Input: [Vegetation Treatment] Shrub-dominated rangeland [Description]

Output: Areas of shrubs with soil covered with residue beneath shrubs, and gaps between shrubs with minimal ground cover. Plants are about 1.2 m tall, with a 0.5 m spacing. The percent cover entered is an indication of the percent of the canopy or ground cover by the vegetation. Examples of this vegetation may be sage-dominated rangeland, or sparsely vegetated pinyon-juniper communities. This treatment may also be a reasonable estimate of a harvested forest 3 years after harvest and prescribed burn, or a forest 4 years after a severe wild fire.

Disturbed WEPP Technical Documentation, Preliminary draft 02/00


Input: [Vegetation Treatment] Tall grass prairie [Description]

Output: Areas covered by tall bunch grasses, with gaps between bunches. Plants are about 0.6 m tall and 0.3 m average spacing. The percent cover entered is an indication of the percent of the canopy or ground covered by the vegetation. This vegetation treatment would best describe blue-stem or similar range communities in the west, or ryegrass, brome, or orchard grass pastures in the east. It may also describe post-fire conditions where wheat or oats have germinated to provide post-fire erosion mitigation. This treatment may also be a reasonable estimate of a harvested forest 2 years after a prescribed burn, or 3 years after a wild fire.

Disturbed WEPP Technical Documentation, Preliminary draft 02/00


Input: [Vegetation Treatment] Short-grass prairie [Description]

Output: Areas covered by short sod-forming grasses. Plants are about 0.4 m tall and with an average spacing of 0.2 m. The percent cover entered is an indication of the percent canopy or ground covered by the vegetation. This vegetation treatment would best describe buffalo grass or similar sodding grasses in the west, or Kentucky bluegrass in the east. It may also best describe sparsely-covered reclaimed mine lands. This treatment may best describe forest conditions 1 year after a prescribed fire or two years after a wild fire.

Disturbed WEPP Technical Documentation, Preliminary draft 02/00


Input: [Vegetation Treatment] Low-severity fire [Description]

Output: This condition describes areas that have either had a low-severity fire, or a successful prescribed fire. Vegetation is assumed to reach an maximum height of 0.2 m and at a spacing of 0.2 m. This is probably the most appropriate treatment to describe a sparsely vegetated, newly exposed surface following excavation where material has not been highly compacted, such as a road cut. The user enters an estimate of the vegetated cover, which may be zero. This treatment may best describe forest conditions the year of a prescribed fire, or conditions 1 year after a wild fire. If there has been a high severity fire, and the soils are NOT hydrophobic, this is probably the best selection, but with a cover reduced to 15 percent, or that observed on the site.

Disturbed WEPP Technical Documentation, Preliminary draft 02/00


Input: [Vegetation Treatment] High-severity fire [Description]

Output: This condition describes areas that have experienced a high-severity fire and soils are hydrophobic (or water repellant). Vegetation is assumed to reach a maximum height of 0.15 m with a spacing of 0.15 m.

Disturbed WEPP Technical Documentation, Preliminary draft 02/00


Input: [Vegetation Treatment] Skid trail [Description]

Output: This condition describes a skid trail with vegetation reaching a maximum height of 0.15 m at a 0.1 m spacing. The soil is assumed to be compacted. This treatment would also describe any site mechanically disturbed and compacted --as long as the user estimates the amount of cover--such as landings, forwarder tracks, skyline paths, etc. If the soils remain compacted during the regeneration period, then the user is advised to use the skid trail for the first five years of regeneration, using increasing amounts of cover to describe local conditions. The time required to achieve 100 percent cover may be as short as 2 years in Eastern forests.

Disturbed WEPP Technical Documentation, Preliminary draft 02/00


Input: MicroclustersÂ® [MegaHydrate (capsule)] YES 50% more than MegaH [Crystal Energy (fluid)]

Output: YES

Dr. Patrick Flanagan MegaHydrate - Detox Products - Oxyhealth


Input: Silica Hydride (or MicroclustersÂ® with Negatively-Ionized Hydrogen) [MegaHydrate (capsule)] YES [Crystal Energy (fluid)]

Output: NO

Dr. Patrick Flanagan MegaHydrate - Detox Products - Oxyhealth


Input: Most Powerful Antioxidant [MegaHydrate (capsule)] YES [Crystal Energy (fluid)]

Output: NO

Dr. Patrick Flanagan MegaHydrate - Detox Products - Oxyhealth


Input: Increase ATP Production [MegaHydrate (capsule)] YES [Crystal Energy (fluid)]

Output: NO

Dr. Patrick Flanagan MegaHydrate - Detox Products - Oxyhealth


Input: Increases Hydration [MegaHydrate (capsule)] YES best option [Crystal Energy (fluid)]

Output: YES best option

Dr. Patrick Flanagan MegaHydrate - Detox Products - Oxyhealth


Input: Reduce Pain & Inflammation [MegaHydrate (capsule)] YES [Crystal Energy (fluid)]

Output: NO

Dr. Patrick Flanagan MegaHydrate - Detox Products - Oxyhealth


Input: Anti-Aging Properties [MegaHydrate (capsule)] YES [Crystal Energy (fluid)]

Output: YES

Dr. Patrick Flanagan MegaHydrate - Detox Products - Oxyhealth


Input: Increase Zeta Potential of Human Cells [MegaHydrate (capsule)] YES [Crystal Energy (fluid)]

Output: YES

Dr. Patrick Flanagan MegaHydrate - Detox Products - Oxyhealth


Input: Neutralizes Harmful Toxins like Fluoride, Chlorine, etc. [MegaHydrate (capsule)] YES AND Converts Chromium 6 to safer Chromium 3 [Crystal Energy (fluid)]

Output: YES

Dr. Patrick Flanagan MegaHydrate - Detox Products - Oxyhealth


Input: Increase Absorption of other Supplements [MegaHydrate (capsule)] YES [Crystal Energy (fluid)]

Output: YES best option

Dr. Patrick Flanagan MegaHydrate - Detox Products - Oxyhealth


Input: Lowers surface tension of water you drink [MegaHydrate (capsule)] YES [Crystal Energy (fluid)]

Output: YES best option

Dr. Patrick Flanagan MegaHydrate - Detox Products - Oxyhealth


Input: Alkalize the body [MegaHydrate (capsule)] YES [Crystal Energy (fluid)]

Output: YES best option

Dr. Patrick Flanagan MegaHydrate - Detox Products - Oxyhealth


Input: Recommended Dosage with 8 oz of Water [MegaHydrate (capsule)] Two to Four Capsules a Day [Crystal Energy (fluid)]

Output: 8 drops every 8 oz of water

Dr. Patrick Flanagan MegaHydrate - Detox Products - Oxyhealth


Input: [Nama Chozou-shu] Sweet, creamy scent with an insinuation of rhubarb, calling to mind memories of rhubarb and custard flavoured boiled sweets which have been delicately rubbed with Cheshire cheese Fainter bouquet of yoghurt which has been liberally sprinkled with vanilla-infused crumble topping [Characteristic]

Output: Aroma

Journal of Applied Drink Studies International


Input: [Nama Chozou-shu] A complex mash-up of fresh figs, marzipan, fresh almonds, custard apple (cherimoya) and raisins Offers freshly cut persimmons, sunflower seeds and green melons draped over cold rice pudding [Characteristic]

Output: Flavour

Journal of Applied Drink Studies International


Input: [Nama Chozou-shu] Clear, colourless liquor Clear, colourless liquor [Characteristic]

Output: Colour

Journal of Applied Drink Studies International


Input: [Nama Chozou-shu] An easy-drinking, smooth beverage which could easily accompany light meals A drier sake which would compliment heavier meals but would also be at home alongside sushi, sashimi or salad [Characteristic]

Output: Satisfaction

Journal of Applied Drink Studies International


Input: [Nama Chozou-shu] A frosted-look label with loads of kanji characters adorns a plain, colourless bottle (see figure 1) A deep blue label with white and gold kanji characters and a black and white image of a samurai warrior (see figure 2) [Characteristic]

Output: Vessel Design

Journal of Applied Drink Studies International


Input: [Nama Chozou-shu] 6.5 6 [Characteristic]

Output: Drinkability

Journal of Applied Drink Studies International


Input: [Possible Severe Side Effects] Intraocular Pressure [MACHISMO] No [Viagra] Yes [Cialis] Yes [Levitra]

Output: No


Input: [Possible Severe Side Effects] Myocardial Infarction [MACHISMO] No [Viagra] Yes [Cialis] Yes [Levitra]

Output: Yes


Input: [Possible Severe Side Effects] Severe Hypotension [MACHISMO] No [Viagra] Yes [Cialis] Yes [Levitra]

Output: Yes


Input: [Possible Severe Side Effects] Stroke [MACHISMO] No [Viagra] Yes [Cialis] No [Levitra]

Output: No


Input: [Possible Severe Side Effects] Sudden Death [MACHISMO] No [Viagra] Yes [Cialis] Yes [Levitra]

Output: Yes


Input: [Possible Severe Side Effects] Ventricular Arrhythmias [MACHISMO] No [Viagra] Yes [Cialis] Yes [Levitra]

Output: Yes


Input: [Type of Testing] BMI measurement [Description]

Output: A measurement that compares a person's height and weight.

the Scale | News content from Club Industry

Seven Ways to Measure Your Clients' Body Fat and Metabolism


Input: [Type of Testing] Underwater weighing [Description]

Output: Compares a person's weight on land to his or her weight in a pool. The more you float, the more fat you have in your body.

the Scale | News content from Club Industry


Input: [Type of Testing] Dual-energy X-ray absorptiometry [Description]

Output: Doctors use low-dose X-rays to measure bone and soft tissue mass.

the Scale | News content from Club Industry


Input: [Type of Testing] Bioelectrical impedance [Description]

Output: As you step on the metal plates of a scale, an electrical signal is sent through your body.

the Scale | News content from Club Industry


Input: [Type of Testing] Resting metabolic rate [Description]

Output: Calculates the number of calories that your body burns by measuring oxygen consumption.

the Scale | News content from Club Industry


Input: [Type of Testing] Skin fold test [Description]

Output: Calipers pinch skin folds to determine your body fat percentage.

the Scale | News content from Club Industry


Input: [Type of Testing] VO2 max [Description]

Output: Measures the volume of oxygen you can consume while exercising at your maximum capacity.

the Scale | News content from Club Industry


Input: [0] No. 9 [Place] 1st [Comments]

Output: Garden planted with architectural plants in pots to include tree ferns make a low maintenance contemporary floral display.


Input: [0] No. 3 [Place] 2nd [Comments]

Output: A well maintained garden using shrubs in pots to include Cordyline and Hydrangea.


Input: [0] No. 4 [Place] 2nd [Comments]

Output: Architectural planting with traditional shrubs in pots make give seasonality.


Input: [0] No. 8 [Place] 3rd [Comments]

Output: Rupert Bear tends the roses in this garden. Very nice it is too.


Input: [0] No. 1 [Place] 1st [Comments]

Output: Cottage style garden, well maintained with excellent array of planting giving an excellent display.


Input: [0] No. 14 [Place] 2nd [Comments]

Output: Seasonal colour, lots of flower pots and well maintained.


Input: [0] No. 54 [Place] 1st [Comments]

Output: Contemporary front garden using random laid black paving and brickwork, punctuated with box ball hedging and planted in a traditional way. Good variety of plants and shrubs to include , Roses, Canna and ferns to give all year round seasonal interest.


Input: [0] No. 33 [Place] 2nd [Comments]

Output: Garden laid on a diagonal using random laid sandstone paving. Planting needs time to mature but undoubtedly will look fantastic in the future.


Input: [0] No. 55 [Place] 3rd [Comments]

Output: Red brick path with low maintenance puddled slate centre piece providing interesting colour and textures.


Input: [0] No. 38 [Place] Highly commended [Comments]

Output: A well maintained neat and tidy garden.


Input: [0] No. 35 [Place] Highly commended [Comments]

Output: A garden full of pots and geodes provide with varied plant choices make this garden visually very interesting and fun.


Input: [0] No. 62 [Place] 1st [Comments]

Output: Granite sett/pea shingle entrance planted in a cottage style with a good choice of plants and seasonality.


Input: [0] No. 70 [Place] 2nd [Comments]

Output: The living arch will provides a spectacular focal point. Good choice of materials providing interesting colour and texture.


Input: [0] No. 83 [Place] 3rd [Comments]

Output: A charming garden with a good choice of plants for seasonal colour.


Input: [0] No. 135 [Place] 1st [Comments]

Output: Lovely, low maintenance garden with interesting plants and textures. The use of flower pots give the garden structure and seasonal interest.


Input: [0] No. 126 [Place] 2nd [Comments]

Output: A pretty cottage style garden using brick- on- edge to form a circular focal point. A good array of planting to include Hydrangeas, Euonymus, Fuchsia, Roses and Pyracantha.


Input: [0] No. 108 [Place] 3rd [Comments]

Output: A stunning display of planting to include Lavender, Fuchsia, and Hydrangea. Flower pots and window box give a beautiful floral display.


Input: [TOPIC] A Abdominal Aortic Aneurysm [REC] B [NOTES]

Output: Recommend one-time screening for abdominal aortic aneurysm (AAA) by ultrasonography in men aged 65 to 75 who have ever smoked. Good evidence on benefit & harms. Harms = increased surgical and psychological morbidity. Conclusion: moderated benefit outweighs harms for male smokers, age 65-75.


Input: [TOPIC] B Bacterial Vaginosis in Pregnancy [REC] D, I [NOTES]

Output: Good studies, conflicting results. Many studies showed benefit, largest did not. Recommends against screening asymptomatic women at low risk for pre-term delivery. For women with history of pre-term delivery, evidence from good quality studies is conflicting with respect to benefits.


Input: [TOPIC] Bacteriuria [REC] A [NOTES]

Output: Good evidence that screening pregnant women for asymptomatic bacteriuria with urine culture significantly reduces symptomatic urinary tract infections, low birth weight, and preterm delivery. Not true for non-pregnant women or men.


Input: [TOPIC] Bladder Cancer [REC] D [NOTES]

Output: Fair evidence that screening with available tests can detect bladder cancer in asymptomatic individuals. Potential benefit of screening would be small for the following reasons: fair evidence that many of the cancers detected by screening have low tendency to progress to invasive disease; relatively low overall prevalence of asymptomatic bladder cancer that would eventually lead to important clinical consequences; limited evidence that early treatment of bladder cancer detected through screening improves long-term health outcomes.


Input: [TOPIC] Blood Pressure [REC] A [NOTES]

Output: Good evidence that blood pressure measurement can identify adults at increased risk for cardiovascular disease due to high blood pressure, and good evidence that treatment of high blood pressure substantially decreases the incidence of cardiovascular disease and causes few major harms.


Input: [TOPIC] Breast Cancer [REC] B [NOTES]

Output: For biennial screening mammography in women aged 40 to 49 years, there is moderate certainty that the net benefit is small. Although the USPSTF recognizes that the benefit of screening seems equivalent for women aged 40 to 49 years and 50 to 59 years, the incidence of breast cancer and the consequences differ. The USPSTF emphasizes the adverse consequences for most women—who will not develop breast cancer—and therefore use the number needed to screen to save 1 life as its metric. By this metric, the USPSTF concludes that there is moderate evidence that the net benefit is small for women aged 40 to 49 years. For biennial screening mammography in women aged 50 to 74 years, there is moderate certainty that the net benefit is moderate. For screening mammography in women 75 years or older, evidence is lacking and the balance of benefits and harms cannot be determined.


Input: [TOPIC] C Carotid Artery Stenosis [REC] I [NOTES]

Output: Insufficient evidence to recommend for or against screening asymptomatic persons for carotid artery stenosis using physical examination or carotid ultrasound. For selected high-risk patients, a recommendation to discuss the potential benefits of screening and carotid endarterectomy may be made on other grounds. All persons should be screened for hypertension, and clinicians should provide counseling about smoking cessation.


Input: [TOPIC] Cervical Cancer [REC] A [NOTES]

Output: Good evidence from multiple observational studies that screening with Pap smears reduces incidence of and mortality from cervical cancer. USPSTF recommends screening for cervical cancer in women ages 21 to 65 years with cytology (Pap smear) every 3 years or, for women ages 30 to 65 years who want to lengthen the screening interval, screening with a combination of cytology and human papillomavirus (HPV) testing every 5 years. USPSTF recommends against screening for cervical cancer in women younger than age 21 years See the Clinical Considerations for discussion of cytology method, HPV testing, and screening interval. Consider stopping screening > 65 y/o if women has had adequate screening with 3 negative findings in past and no abnormal Pap tests in 10 yrs. Be alert to screen any women who has not had adequate screening in past.


Input: [TOPIC] Chlamydial Infection [REC] A [NOTES]

Output: Good evidence that screening women at risk for chlamydial infection reduces the incidence of pelvic inflammatory disease and fair evidence that community-based screening reduces prevalence of chlamydial infection. Routinely screen all sexually active women aged 24 years and younger (including those pregnant), and other asymptomatic women at increased risk for chlamydial infection.


Input: [TOPIC] Colorectal Cancer [REC] A [NOTES]

Output: Strongly recommends that clinicians screen men and women 50 years of age or older for colorectal cancer. Fair to good evidence that several screening methods are effective in reducing mortality from colorectal cancer. Benefits from screening substantially outweigh potential harms, but the quality of evidence, magnitude of benefit, and potential harms vary with each method (FOB testing, flex sig, colonoscopy). Initiate screening at 50 years of age for men and women at average risk for colorectal cancer. In persons at higher risk (for example, those with a first-degree relative who receives a diagnosis with colorectal cancer before 60 years of age), initiating screening at an earlier age is reasonable.


Input: [TOPIC] Coronary Heart Disease [REC] D,I [NOTES]

Output: Recommends against routine screening with resting ECG, exercise testing (ETT), or scanning for coronary calcium for either the presence of severe coronary artery stenosis (CAS) or the prediction of coronary heart disease (CHD) events in adults at low risk for CHD events. Found insufficient evidence to recommend for or against routine screening with ECG, ETT, or EBCT scanning for coronary calcium in adults at increased risk for CHD events.


Input: [TOPIC] D Dementia [REC] I [NOTES]

Output: Evidence is insufficient to recommend for or against routine screening for dementia in older adults.


Input: [TOPIC] Depression [REC] B [NOTES]

Output: Good evidence that screening improves the accurate identification of depressed patients in primary care settings and that treatment of depressed adults identified in primary care settings decreases clinical morbidity. Insufficient evidence to recommend screening for adolescents and children.


Input: [TOPIC] Diabetes Mellitus [REC] I, B [NOTES]

Output: The evidence is insufficient to recommend for or against routinely screening asymptomatic adults for type 2 diabetes, impaired glucose tolerance, or impaired fasting glucose. Good evidence to screen patients with hyperlipidemia, and those with hypertension, since lowering blood pressure to below conventional target ranges is deemed beneficial in diabetic hypertensives..


Input: [TOPIC] Diet [REC] B,I [NOTES]

Output: Recommends intensive behavioral dietary counseling for adult patients with hyperlipidemia and other known risk factors for cardiovascular and diet-related chronic disease. Intensive counseling can be delivered by primary care clinicians or by referral to other specialists, such as nutritionists or dietitians. Insufficient evidence to determine the significance and magnitude of the benefit of routine counseling to promote a healthy diet in adults


Input: [TOPIC] Down Syndrome [REC] B,B [NOTES]

Output: The offering of amniocentesis or chorionic villus sampling (CVS) for chromosome studies is recommended by the USPSTF for pregnant women at high risk for Down syndrome. The offering of screening for Down syndrome by serum multiple-marker testing is recommended for: · All low-risk pregnant women. · As an alternative to amniocentesis and CVS for high-risk women.


Input: [TOPIC] Drug Abuse [REC] I [NOTES]

Output: There is insufficient evidence to recommend for or against routine screening for drug abuse with standardized questionnaires or biologic assays. Including questions about drug use and drug-related problems when taking a history from all adolescent and adult patients may be recommended on other grounds.All pregnant women should be advised of the potential adverse effects of drug use on the development of the fetus.Clinicians should be alert to the signs and symptoms of drug abuse in patients and refer drug abusing patients to specialized treatment facilities where available.


Input: [TOPIC] F Family Violence: [REC] I [NOTES]

Output: Found no direct evidence that screening for family and intimate partner violence leads to decreased disability or premature death. The USPSTF found fair to good evidence that interventions reduce harm to children when child abuse or neglect has been suspected and assessed.


Input: [TOPIC] G Gestational Diabetes [REC] I [NOTES]

Output: Fair to good evidence that screening combined with diet and insulin therapy can reduce the rate of fetal macrosomia in women with gestational diabetes mellitus (GDM). The USPSTF found insufficient evidence, however, that screening for GDM substantially reduces important adverse health outcomes for mothers or their infants (for example, cesarean delivery, birth injury, or neonatal morbidity or mortality). Risk factors for GDM include maternal obesity (usually defined as a body mass index [BMI] of 25 or more), older age (usually defined as older than 25 years), family or personal history of diabetes, or a history of GDM in a prior pregnancy. Expert groups have also identified certain ethnic groups as being at increased risk for GDM (such as Hispanic, African American, American Indian, and South or East Asian). Using all the above criteria, however, would identify 90 percent of all pregnant women as being at increased risk for GDM. The optimal approach to screening and diagnosis is uncertain. Expert panels in the United States recommend a 50-g 1-hour glucose challenge test (GCT) at 24 to 28 weeks' gestation, followed by a 100-g 3-hour oral glucose tolerance test (OGTT) for women who screen positive on the GCT.


Input: [TOPIC] Glaucoma [REC] I [NOTES]

Output: Good evidence that screening can detect increased intraocular pressure (IOP) and early primary open-angle glaucoma (POAG) in adults. The USPSTF also found good evidence that early treatment of adults with increased IOP detected by screening reduces the number of persons who develop small, visual field defects, and that early treatment of those with early, asymptomatic POAG decreases the number of those whose visual field defects progress. The evidence, however, is insufficient to determine the extent to which screening—leading to the earlier detection and treatment of people with IOP or POAG—would reduce impairment in vision-related function or quality of life


Input: [TOPIC] Gonorrhea [REC] B [NOTES]

Output: Fair evidence that screening tests can accurately detect gonorrhea infection and good evidence that antibiotics can cure gonorrhea infection. There is fair evidence that screening pregnant women at high risk for gonorrhea, including women at high risk because of younger age, may prevent other complications associated with gonococcal infection during pregnancy, such as preterm delivery and chorioamnionitis. Risk factors for gonorrhea include a history of previous gonorrhea infection, other sexually transmitted infections, new or multiple sexual partners, inconsistent condom use, sex work, and drug use.


Input: [TOPIC] H Hearing Impairment [REC] B [NOTES]

Output: Screening for older adults for hearing impairment is recommended through: Periodically questioning them about their hearing. Counseling them about the availability of hearing aid devices. Making referrals for abnormalities when appropriate.


Input: [TOPIC] Hearing, Newborn [REC] I [NOTES]

Output: Good evidence that newborn hearing screening leads to earlier identification and treatment of infants with hearing loss. However, evidence to determine whether earlier treatment resulting from screening leads to clinically important improvement in speech and language skills at age 3 years or beyond is inconclusive because of the design limitations in existing studies. The USPSTF found good evidence that the prevalence of hearing loss in infants in the newborn intensive care unit (NICU) and those with other specific risk factors is 10 to 20 times higher than the prevalence of hearing loss in the general population of newborns. Both the yield of screening and the proportion of true positive results will be substantially higher when screening is targeted at these high-risk infants. Evidence that early identification and intervention for hearing loss improves speech, language, or auditory outcomes in high-risk populations is also limited.


Input: [TOPIC] Hemoglobinopathies [REC] B,I [NOTES]

Output: Neonatal screening for sickle hemoglobinopathies is recommended to identify infants who may benefit from antibiotic prophylaxis to prevent sepsis. Whether screening should be universal or targeted to high-risk groups will depend on: The proportion of high-risk individuals in the screening area. The accuracy and efficiency with which infants at risk can be identified. Other characteristics of the screening program. Offering screening for hemoglobinopathies to pregnant women at the first prenatal visit is recommended, especially for those at high risk. There is insufficient evidence to recommend for or against routine screening for hemoglobinopathies in high-risk adolescents and young adults, but recommendations to offer such testing may be made on other grounds. All screening efforts must be accompanied by comprehensive counseling and treatment services.


Input: [TOPIC] Hepatitis B Virus Infection [REC] A,D [NOTES]

Output: Good evidence that universal prenatal screening for HBV infection using HBsAg substantially reduces prenatal transmission of HBV and the subsequent development of chronic HBV infection. The current practice of vaccinating all infants against HBV infection and postexposure prophylaxis with hepatitis B immune globulin administered at birth to infants of HBV-infected mothers substantially reduces the risk for acquiring HBV infection. No evidence that screening the general population for HBV infection improves long-term health outcomes such as cirrhosis, hepatocellular carcinoma, or mortality. The prevalence of HBV infection is low; the majority of infected individuals do not develop chronic infection, cirrhosis, or HBV-related liver disease.


Input: [TOPIC] Hepatitis C Virus Infection [REC] D,I [NOTES]

Output: Good evidence that screening with available tests can detect HCV infection in the general population. The prevalence of HCV infection in the general population is low, and most who are infected do not develop cirrhosis or other major negative health outcomes. There is no evidence that screening for HCV infection leads to improved long-term health outcomes, such as decreased cirrhosis, hepatocellular cancer, or mortality. No evidence that screening for HCV infection in adults at high risk leads to improved long-term health outcomes, although the yield of screening would be substantially higher in a high-risk population than in an average-risk population and there is good evidence that anti-viral therapy improves intermediate outcomes, such as viremia. There is, as yet, no evidence that newer treatment regimens for HCV infection, such as pegylated interferon plus ribavirin, improve long-term health outcomes.


Input: [TOPIC] Herpes Simplex, Genital [REC] D [NOTES]

Output: Fair evidence that screening asymptomatic pregnant women using serological screening tests for HSV antibody does not reduce transmission of HSV to newborn infants. Women who develop primary HSV infection during pregnancy have the highest risk for transmitting HSV infection to their infants. Because these women are initially seronegative, serological screening tests for HSV (enzyme-linked immunosorbent assay [ELISA], immunoblot, and western blot assay [WBA]) do not accurately detect those at highest risk. No evidence that screening asymptomatic adolescents and adults with serological tests for HSV antibody improves health outcomes or symptoms or reduces transmission of disease.


Input: [TOPIC] Hormone Replacement Therapy [REC] D [NOTES]

Output: Good evidence that the use of combined estrogen and progestin results in both benefits and harms. Benefits include reduced risk for fracture (good evidence) and colorectal cancer (fair evidence). Combined estrogen and progestin has no beneficial effect on coronary heart disease and may even pose an increased risk (good evidence). Other harms include increased risk for breast cancer (good evidence), venous thromboembolism (good evidence), stroke (fair evidence), cholecystitis (fair evidence), dementia (fair evidence), and lower global cognitive function (fair evidence).


Input: [TOPIC] Household and Recreational Injuries [NOTES]

Output: Periodic counseling of the parents of children on measures to reduce the risk of unintentional household and recreational injuries is recommended. Counseling to prevent household and recreational injuries is also recommended for adolescents and adults based on the proven efficacy of risk reduction, although the effectiveness of counseling these patients to prevent injuries has not been adequately evaluated. Persons with alcohol or drug problems should be identified, counseled and monitored. Those who use alcohol or illicit drugs should be warned against engaging in potentially dangerous activities while intoxicated. Counseling elderly patients on specific measures to prevent falls is recommended based on fair evidence that these measures reduce the risk of falls, although the effectiveness of counseling elders to prevent falls has not been adequately evaluated. More intensive individualized multi-factorial intervention is recommended for high-risk elderly patients in settings where adequate resources to deliver such services are available. There is insufficient evidence to recommend for or against the use of external hip protectors to prevent fall injuries.


Input: [TOPIC] Human Immunodeficiency Virus (HIV) Infection [REC] A [NOTES]

Output: Good evidence that rapid screening tests accurately detect HIV infection. The USPSTF also found good evidence that appropriately timed interventions, particularly highly active antiretroviral therapy (HAART), lead to improved health outcomes for many of those screened, including reduced risk for clinical progression and reduced mortality. Since false-positive test results are rare, harms associated with HIV screening are minimal. Potential harms of true-positive test results include increased anxiety, labeling, and effects on close relationships. Most adverse events associated with HAART, including metabolic disturbances associated with an increased risk for cardiovascular events, may be ameliorated by changes in regimen or appropriate treatment. The USPSTF concluded that the benefits of screening individuals at increased risk substantially outweigh potential harms.


Input: [TOPIC] Hypothyroidism, Congenital [REC] A [NOTES]

Output: Screening for congenital hypothyroidism with thyroid function tests on dried-blood spot specimens is recommended for all newborns in the first week of life.


Input: [TOPIC] L Lead Levels in Childhood and Pregnancy [NOTES]

Output: Screening for elevated lead levels by measuring blood lead at least once at age 12 months is recommended for: All children at increased risk of lead exposure. All children with identifiable risk factors. All children living in communities in which the prevalence of blood lead levels requiring individual intervention, including residential lead hazard control or chelation therapy, is high or is undefined.


Input: [TOPIC] Lipid Disorders [REC] A,B [NOTES]

Output: Good evidence that lipid measurement can identify asymptomatic middle-aged people (men > 35, women > 45) at increased risk of coronary heart disease and good evidence that lipid-lowering drug therapy substantially decreases the incidence of coronary heart disease in such people with abnormal lipids and causes few major harms. Recommends that clinicians routinely screen younger adults (men aged 20 to 35 and women aged 20 to 45) for lipid disorders if they have other risk factors for coronary heart disease.


Input: [TOPIC] Lung Cancer [REC] I [NOTES]

Output: Evidence is insufficient to recommend for or against screening asymptomatic persons for lung cancer with either low dose computerized tomography (LDCT), chest x-ray (CXR), sputum cytology, or a combination of these tests


Input: [TOPIC] Motor Vehicle Injuries [NOTES]

Output: The following counseling to all patients, and the parents of young patients, is recommended: Use occupant restraints (lap/shoulder safety belts and child safety seats). Wear helmets when riding motorcycles. Refrain from driving while under the influence of alcohol or other drugs.


Input: [TOPIC] O Overweight in Children and Adolescents [REC] I [NOTES]

Output: Approximately 15 percent of children and adolescents aged 6 to 19 years are overweight and are at risk for diabetes, elevated blood lipids, increased blood pressure and their sequelae, as well as slipped capital femoral epiphysis, steatohepatitis, sleep apnea, and psychosocial problems. The USPSTF found fair evidence that body mass index (BMI) is a reasonable measure for identifying children and adolescents who are overweight or are at risk for becoming overweight. There is fair evidence that overweight adolescents and children aged 8 years and older are at increased risk for becoming obese adults. The USPSTF found insufficient evidence for the effectiveness of behavioral counseling or other preventive interventions with overweight children and adolescents that can be conducted in primary care settings or to which primary care clinicians can make referrals. There is insufficient evidence to ascertain the magnitude of the potential harms of screening or prevention and treatment interventions. The USPSTF was, therefore, unable to determine the balance between potential benefits and harms for the routine screening of children and adolescents for overweight.


Input: [TOPIC] Obesity in Adults [REC] I [NOTES]

Output: Found good evidence that body mass index (BMI) is reliable and valid for identifying adults at increased risk for mortality and morbidity due to overweight and obesity. There is fair to good evidence that high-intensity counseling—about diet, exercise, or both—together with behavioral interventions aimed at skill development, motivation, and support strategies produces modest, sustained weight loss (typically 3-5 kg for 1 year or more) in adults who are obese (as defined by BMI > 30 kg/m2). Although the USPSTF did not find direct evidence that behavioral interventions lower mortality or morbidity from obesity, the USPSTF concluded that changes in intermediate outcomes, such as improved glucose metabolism, lipid levels, and blood pressure, from modest weight loss provide indirect evidence of health benefits


Input: [TOPIC] Oral Cancer [REC] I [NOTES]

Output: No good-quality evidence that screening for oral cancer leads to improved health outcomes for either high-risk adults (i.e., those over the age of 50 who use tobacco) or for average-risk adults in the general population.


Input: [TOPIC] Osteoporosis [REC] B [NOTES]

Output: USPSTF recommends screening for osteoporosis in women aged 65 years or older and in younger women whose fracture risk is equal to or greater than that of a 65-year-old white woman who has no additional risk factors.


Input: [TOPIC] Ovarian Cancer [REC] D [NOTES]

Output: Fair evidence that screening with serum CA-125 level or transvaginal ultrasound can detect ovarian cancer at an earlier stage than it can be detected in the absence of screening; however, the USPSTF found fair evidence that earlier detection would likely have a small effect, at best, on mortality from ovarian cancer. Because of the low prevale e of ovarian cancer and the invasive nature of diagnostic testing after a positive screening test, there is fair evidence that screening could likely lead to important harms.


Input: [TOPIC] P Pancreatic Cancer: [REC] D [NOTES]

Output: No evidence that screening for pancreatic cancer is effective in reducing mortality. There is a potential for significant harm due to the very low prevalence of pancreatic cancer, limited accuracy of available screening tests, the invasive nature of diagnostic tests, and the poor outcomes of treatment


Input: [TOPIC] Peripheral Arterial Disease [REC] D [NOTES]

Output: Fair evidence that screening with ankle brachial index can detect adults with asymptomatic PAD. The evidence is also fair that screening for PAD among asymptomatic adults in the general population would have few or no benefits because the prevalence of PAD in this group is low and because there is little evidence that treatment of PAD at this asymptomatic stage of disease, beyond treatment based on standard cardiovascular risk assessment, improves health outcomes.


Input: [TOPIC] Phenylketonuria [REC] A [NOTES]

Output: Screening for phenylketonuria (PKU) by measurment of phenylalanine level on a dried-blood spot specimen is recommended for all newborns prior to discharge from the nursery. Infants who are tested before 24 hours of age should receive a repeat screening test by 2 weeks of age.


Input: [TOPIC] Physical Activity [REC] I [NOTES]

Output: Insufficient evidence to determine whether counseling patients in primary care settings to promote physical activity leads to sustained increases in physical activity among adult patients. Controlled trials of physical activity counseling in adult primary care patients were of variable quality and had mixed results. There were no completed trials with children or adolescents that compared counseling with usual care practices. The USPSTF reviewed only the literature on the effectiveness of primary care counseling to promote physical activity. It did not review the evidence for the effectiveness of physical activity to reduce chronic disease morbidity and mortality, which has been well documented in other recent reviews, or review evidence of counseling in other settings.


Input: [TOPIC] Postexposure Prophylaxis for Selected Infectious Diseases [NOTES]

Output: Postexposure prophylaxis should be provided to selected persons with exposure or possible exposure to: Haemophilus influenzae type b. Hepatitis A. Hepatitis B. Meningococcal pathogens. Rabies pathogens Tetanus pathogens


Input: [TOPIC] Preeclampsia [REC] B [NOTES]

Output: Screening for preeclampsia with blood pressure measurement is recommended for all pregnant women at the first prenatal visit and periodically throughout the remainder of the pregnancy.


Input: [TOPIC] Prostate Cancer: [REC] D [NOTES]

Output: The USPSTF recommends against PSA-based screening for prostate cancer. Good evidence that PSA screening can detect early-stage prostate cancer but mixed and inconclusive evidence that early detection improves health outcomes. Screening is associated with important harms, including frequent false-positive results and unnecessary anxiety, biopsies, and potential complications of treatment of some cancers that may never have affected a patient's health.


Input: [TOPIC] R Rh Incompatibility [REC] A,B [NOTES]

Output: Good evidence that Rh (D) blood typing, anti-Rh (D) antibody testing, and intervention with Rh (D) immunoglobulin, as appropriate, prevents maternal sensitization and improves outcomes for newborns. The benefits substantially outweigh any potential harms. Fair evidence that repeated antibody testing for unsensitized Rh (D)-negative women (unless the father is also known to be Rh [D]-negative) and intervention with Rh (D) immunoglobulin, as appropriate, provides additional benefit over a single test at the first prenatal visit in preventing maternal sensitization and improving outcomes for newborns.


Input: [TOPIC] Rubella [NOTES]

Output: Routine screening for rubella susceptibility by history of vaccination or by serology is recommended for all women of childbearing age at their first clinical encounter. Susceptible non-pregnant women should be offered rubella vaccination; susceptible pregnant women should be vaccinated immediately after delivery. An equally acceptable alternative for non-pregnant women of childbearing age is to offer vaccination against rubella without screening.


Input: [TOPIC] S Skin Cancer: [REC] I [NOTES]

Output: Evidence is insufficient to recommend for or against routine screening for skin cancer using a total-body skin examination for the early detection of cutaneous melanoma, basal cell cancer, or squamous cell skin cancer. Also insufficient evidence to determine whether clinician counseling is effective in changing patient behaviors to reduce skin cancer risk. Counseling parents may increase the use of sunscreen for children, but there is little evidence to determine the effects of counseling on other preventive behaviors (such as wearing protective clothing, reducing excessive sun exposure, avoiding sun lamps/tanning beds, or practicing skin self-examination) and little evidence on potential harms.


Input: [TOPIC] Suicide Risk [REC] I [NOTES]

Output: No evidence that screening for suicide risk reduces suicide attempts or mortality. There is limited evidence on the accuracy of screening tools to identify suicide risk in the primary care setting, including tools to identify those at high risk. There is insufficient evidence that treatment of those at high risk reduces suicide attempts or mortality.


Input: [TOPIC] Syphilis [REC] A [NOTES]

Output: Strongly recommends that clinicians screen persons at increased risk for syphilis infection. Observational evidence that the universal screening of pregnant women decreases the proportion of infants with clinical manifestations of syphilis infection and those with positive serologies.


Input: [TOPIC] T Testicular Cancer [REC] D [NOTES]

Output: No new evidence that screening with clinical examination or testicular self-examination is effective in reducing mortality from testicular cancer. Even in the absence of screening, the current treatment interventions provide very favorable health outcomes. Given the low prevalence of testicular cancer, limited accuracy of screening tests, and no evidence for the incremental benefits of screening, the USPSTF concluded that the harms of screening exceed any potential benefits.


Input: [TOPIC] Thyroid Disease [REC] I [NOTES]

Output: Fair evidence that the thyroid stimulating hormone (TSH) test can detect sub-clinical thyroid disease in people without symptoms of thyroid dysfunction, but poor evidence that treatment improves clinically important outcomes in adults with screen-detected thyroid disease. Although the yield of screening is greater in certain high-risk groups (e.g., postpartum women, people with Down syndrome, and the elderly), the USPSTF found poor evidence that screening these groups leads to clinically important benefits.


Input: [TOPIC] Thyroid Cancer [REC] D, C [NOTES]

Output: Routine screening for thyroid cancer using neck palpation or ultrasonography is not recommended for asymptomatic children or adults. There is insufficient evidence to recommend for or against screening persons with a history of external head and neck irradiation in infancy or childhood, but recommendations for such screening may be made on other grounds.


Input: [TOPIC] Tobacco Use [REC] A [NOTES]

Output: Good evidence that brief smoking cessation interventions, including screening, brief behavioral counseling (less than 3 minutes), and pharmacotherapy delivered in primary care settings, are effective in increasing the proportion of smokers who successfully quit smoking and remain abstinent after 1 year. Recommends that clinicians screen all pregnant women for tobacco use and provide augmented pregnancy-tailored counseling to those who smoke.


Input: [TOPIC] Tuberculous Infection [REC] A [NOTES]

Output: Screening for tuberculous infection with tuberculin skin testing is recommended for asymptomatic high-risk persons. Bacille Calmette-Guerin (BCG) vaccination should be considered only for selected high-risk individuals.


Input: [TOPIC] U Ultrasonography in Pregnancy [NOTES]

Output: Routine third-trimester ultrasound examination of the fetus is not recommendeed. There is insufficient evidence to recommend for or against routine ultrasound examination in the second trimester in low-risk pregnant women. Despite the lack of evidence on its positive impact on health outcomes and the 1996 USPSTF recommendation against its routine use, ultrasonography in pregnancy has become common practice in the U.S. Based on currently available evidence, the USPSTF believes there would be limited potential impact on clinical practice in updating the 1996 recommendation. The USPSTF will not update its 1996 recommendation.


Input: [TOPIC] Unintended Pregnancy [NOTES]

Output: Periodic counseling about effective contraceptive methods is recommended for all women and men at risk for unintended pregnancy. Counseling should be based on information from a careful sexual history and should take into account the individual preferences, abilities, and risks of each patient. Sexually active patients should also receive information on measures to prevent sexually transmitted diseases.


Input: [TOPIC] V Visual Impairment [NOTES]

Output: Vision screening to detect amblyopia and strabismus is recommended once for all children before entering school, preferably between the ages of 3 and 4. Clinicians should be alert for signs of ocular misalignment when examining infants and children. Screening for diminished visual acuity with the Snellen visual acuity chart is recommended for elderly persons. There is insufficient evidence to recommend for or against screening for diminished visual acuity among other asymptomatic persons, but recommendations against routine screening may be made on other grounds.


Input: [TOPIC] Visual Impairment in Children Ages 0-5 [REC] B [NOTES]

Output: The USPSTF found no direct evidence that screening for visual impairment in children leads to improved visual acuity. However, the USPSTF found fair evidence that screening tests have reasonable accuracy in identifying strabismus, amblyopia, and refractive error in children with these conditions; that more intensive screening compared with usual screening leads to improved visual acuity; and that treatment of strabismus and amblyopia can improve visual acuity and reduce long-term amblyopia.


Input: [TOPIC] Vitamin Supplementation to Prevent Cancer and Coronary Heart Disease [REC] I [NOTES]

Output: Evidence is insufficient to recommend for or against the use of supplements of vitamins A, C, or E; multivitamins with folic acid; or antioxidant combinations for the prevention of cancer or cardiovascular disease.


Input: [TOPIC] Y Youth Violence [NOTES]

Output: There is insufficient evidence to recommend for or against clinician counseling of asymptomatic adolescents and adults to prevent morbidity and mortality from youth violence. Adolescent and adult patients should be screened for problem drinking. Clinicians should also be alert for symptoms and signs of drug abuse and dependence, the various presentations of family violence, and suicidal ideation in persons with established risk factors.


Input: Site is accessible at Mile 1418 of the Alaskan Highway to any traffic Eva Creek site is accessible only by off-road vehicle. A bridge and 20 miles of road needs to be constructed capable of carrying loads in excess of 125,000 pounds Out of respect to the rural nature of the area and the residents of Ferry, GVEA is not considering a bridge across the Nenana River. Instead, GVEA will use the railroad to deliver material and equipment to the project side of the river.The costs of extending the railroad off-loading site as well as the cost of improving the road (7 miles) is included in GVEA’s project cost. [Permitting]

Output: Site Access


Input: Delta Wind Farm has turbine sites fully developed GVEA has not begun any construction at Eva Creek Until the Board makes the final decision on Eva Creek (expected in June), we have not constructed the turbine sites. However, our engineering has identified the exact locations of the turbines to deliver the maximum energy yield. [Permitting]

Output: Shovel Ready


Input: Delta Wind Farm will improve grid efficiency between North Pole and Delta by 7% Eva Creek will compete for the limited space on the Northern Intertie and incurr approximately 7% line losses. This problem will be compounded by the Healy Clean Coal Plant when it comes online. The published engineering study has assured us that the Northern Intertie has sufficient capacity for both Eva Creek and HCCP.All power lines experience line loss. The line losss from Healy to Fairbanks is less than 3%. [Permitting]

Output: Grid Efficiency


Input: Delta Wind Farm has a less volatile wind regime and is not competing for space on the Northern Intertie. For these reasons the cost of integrating Delta Wind Farm’s power is 60% lower than Eva Creek. Eva Creek has more gusty winds than Delta Wind Farm causing larger power swings on GVEA’s grid and costing more to integrate. The cost to integrate both projects is equal, as both are projected to be deliver the same amount of power (24 MW).What’s more important is average wind speed. Eva Creek has an average speed of 7.8 meters per second while Delta Wind has an average speed of 6.6 meters per second. This means Eva Creek will deliver significantly more power over the course of a year (we call this capacity factor). [Permitting]

Output: Integrating Wind Power


Input: Delta Wind Farm could have been fully operational by the end of 2011. Because GVEA has not accepted a proposal by Delta Wind Farm the 2011 construction season has been lost. Delta Wind Farm will instead be finished by November 30, 2012. GVEA has stated their projected finish date to be year’s end 2012. Delta Wind Farm finds this date to be extremely hopeful. The permitting process and road/bridge construction will need to be finished before construction of Eva Creek could begin. Once the Board votes to move ahead with Eva Creek, the project will be scheduled for completion by September 2012.Delta Wind’s last proposal (dated April 11, 2011) has a commercial operation date of August 2012. [Permitting]

Output: Projected Finish Date


Input: Delta Wind Farm will be financed by $43 million in private capital. Delta Wind Farm will not cost the public anything. EVA Creek will be financed through a loan of $93 million to be paid off over 18 years by GVEA members At the February Board meeting, staff reported the estimated cost of Eva Creek at $90 million. However, we expect the price to drop once the final bids are considered in June.The loan for Eva Creek is part of the Federal Stimulus. The interest rate is approximately 2.1% and will be paid off over a 18-year period. All financing costs, for either Eva Creek or Delta Wind, is reflected in the price per kilowatt hour for each project. In Eva Creek’s case, the price per kWh is 9.8 cents per kWh. Delta Wind’s cost is 12.5 cents per kWh. In other words, Eva Creek’s price is 30% less than Delta Wind’s price. [Permitting]

Output: Project Cost


Input: Delta Wind Farm has projected savings of $82 million to GVEA members over a 20 year contract. These savings increase with the cost of a barrel of oil. GVEA’s own projections have shown that Eva Creek will save $13 million over 20 years Delta Wind is priced at 12.5 cents per kilowatt-hour. Eva Creek is priced at 9.8 cents per kilowatt-hour. Over a period of a year that will amount to $2,025,000 more for power from Delta Wind. ((75,000,000 kWh X ($0.125 – $0.098)). [Permitting]

Output: Projected Savings


Input: Delta Wind Farm is essentially a free wind farm for GVEA. No investment by GVEA is necessary. Delta Wind Farm will only be paid for production and at a rate lower than the current avoided fuel cost. The HCCP was ready to produce power in 1999. GVEA member’s over the past 10 years would have saved around $200 million by burning coal over diesel. Fairbanks would also have less air quality concerns. True, members will not pay for Delta Wind directly. But they will pay more in their monthly bills for the power it produces. And yes, we wish HCCP were up and running. Hindsight is 20/20. That is why GVEA is trying to get the EPA to renew our air permit so we can restart the plant and pass the savings on to our members. [Permitting]

Output: Public Financial Risk


Input: Delta Wind Farm entered the energy market 4 years ago. In that time 7 small turbines and 2 commercial scale turbines have been erected at two separate sites. Delta Wind Farm has already produced 1.4 Million kWh, offset 90,000 gallons of diesel, and is ready to expand. GVEA has been studying their Eva Creek site for almost 7 years. They have erected no turbines. Eva Creek is a project that will be paid for by GVEA Members whether it produces power or not. At a time when GVEA is struggling to bring energy costs down GVEA’s sole focus should be on bringing the Healy Clean Coal plant online. We don’t take the responsibility of spending our members’ money lightly. That’s why we’ve studied Eva Creek thoroughly. That’s also why we waited until a wind project came along that did not raise our members’ bills. Eva Creek is GVEA’s best and lowest cost option for renewable energy. [Permitting]

Output: Proven Experience and Follow Through


Input: [Form of Nitrogen] Nitrogen gas [Formula] N2 [Availability for plant uptake]

Output: Although 78% of our atmosphere is nitrogen gas, this form of nitrogen must be transformed to usable forms before it is available for plant uptake.


Input: [Form of Nitrogen] Ammonia [Formula] NH3 [Availability for plant uptake]

Output: Ammonia is a gas. Ammonium can escape from the surface of the soil under certain conditions and is harmful to plants in high quantities. Ammonium is the basic building block of commercial nitrogen fertilizers.


Input: [Form of Nitrogen] Ammonium [Formula] NH4+ [Availability for plant uptake]

Output: Soil particles attract and retain ammonium on cation exchange complexes. This form may be directly taken up by plants.


Input: [Form of Nitrogen] Nitrate [Formula] NO3- [Availability for plant uptake]

Output: Nitrate is the second form of nitrogen which is available for plant uptake. In most soils, nitrate is highly mobile. However, in the highly weathered soils of Hawaii, nitrate is stored in soils with ‘anion exchange capacity’ and becomes less mobile.


Input: [Form of Nitrogen] Nitrite [Formula] NO2- [Availability for plant uptake]

Output: Nitrite is an intermediate product in the conversion of ammonium to nitrate (nitrification). It is usually present in low quantities, but is toxic to plants.


Input: [Form of Nitrogen] Organic Nitrogen [Formula] Various compounds [Availability for plant uptake]

Output: Organic nitrogen must be converted to ammonium before it is used by plants. This conversion occurs with time and is known as mineralization.


Input: [ICD-9-CM Code] V10.46 V10.51 V10.52 V10.53 [Description]

Output: Persons with Potential Health Hazards Related to Personal and Family History (Note: V10.53 added per Medicare Focus December, 2001


Input: [ICD-9-CM Code] V42.0 [Description]

Output: Persons with a Condition Influencing Their Health Status


Input: [ICD-9-CM Code] V58.69 [Description]

Output: Person Encountering Health Services for Specific Procedures and Aftercare


Input: [ICD-9-CM Code] V67.51 [Description]

Output: Persons Encountering Health Services in Other Circumstances


Input: [ICD-9-CM Code] 038.0 - 038.9 [Description]

Output: Other Bacterial Diseases


Input: [ICD-9-CM Code] 185 188.0 - 189.9 [Description]

Output: Malignant Neoplasm of Genitourinary Organs


Input: [ICD-9-CM Code] 222.2 [Description]

Output: Benign Neoplasms


Input: [ICD-9-CM Code] 236.7 [Description]

Output: Neoplasm of Uncertain Behavior of Bladder (Updated in Medicare Focus, May 1999, pg. 12)


Input: [ICD-9-CM Code] 239.4 239.5 [Description]

Output: Disorders of Thyroid Gland


Input: [ICD-9-CM Code] 250.00 - 250.43 [Description]

Output: Diseases of Other Endocrine Glands


Input: [ICD-9-CM Code] 271.4 276.5 [Description]

Output: Other Metabolic and Immunity Disorders


Input: [ICD-9-CM Code] 344.61 [Description]

Output: Other Disorders of the Central Nervous System


Input: [ICD-9-CM Code] 401.0 - 405.99 [Description]

Output: Hypertensive Disease (Updated in Medicare Focus, October, 2001)


Input: [ICD-9-CM Code] 428.0 [Description]

Output: Other Forms of Heart Disease


Input: [ICD-9-CM Code] 446.0 - 446.5 447.6 [Description]

Output: Diseases of Arteries, Arterioles, and Capillaries


Input: [ICD-9-CM Code] 571.2 - 571.6 [Description]

Output: Other Diseases of the Digestive System


Input: [ICD-9-CM Code] 580.0 - 602.8 [Description]

Output: Nephritis, Nephrotic Syndrome, and Nephrosis


Input: [ICD-9-CM Code] 604.0 - 604.99 [Description]

Output: Diseases of Male Genital Organs


Input: [ICD-9-CM Code] 618.0 625.6 [Description]

Output: Other disorders of Female Genital Tract


Input: [ICD-9-CM Code] 634.00 - 638.9 639.3 - 639.5 639.8 [Description]

Output: Other Pregnancy with Abortive Outcome


Input: [ICD-9-CM Code] 642.00 - 642.94 644.00 - 644.21 646.20 646.50 - 646.60 [Description]

Output: Complications Mainly Related to Pregnancy


Input: [ICD-9-CM Code] 669.30 - 669.34 [Description]

Output: Complications Occurring Mainly in the Course of Labor and Delivery


Input: [ICD-9-CM Code] 710.0 -710.9 711.00 - 711.09 714.0 [Description]

Output: Arthropathies and Related Disorders


Input: [ICD-9-CM Code] 725 [Description]

Output: Rheumatism, Excluding the Back


Input: [ICD-9-CM Code] 753.10 - 753.19 [Description]

Output: Congenital Anomalies


Input: [ICD-9-CM Code] 780.6 782.3 783.21 Revised per Medicare Focus December, 2000 788.0 - 789.09 [Description]

Output: Symptoms


Input: [ICD-9-CM Code] 790.93 791.0 - 791.9 [Description]

Output: Nonspecific Abnormal Findings


Input: [ICD-9-CM Code] 866.0 - 866.13 867.0 - 867.1 867.2 - 867.3 867.6 [Description]

Output: Internal Injury of Thorax, Abdomen and Pelvis


Input: [ICD-9-CM Code] 959.1 [Description]

Output: Certain Traumatic Complications and Unspecified Injuries


Input: [ICD-9-CM Code] 982.2 985.0 [Description]

Output: Toxic Effects of Substances Chiefly Non-Medicine As To Source


Input: [SK115LF65AC] 85.2 x 87.2 x 23.5 mm [Model No]

Output: Overall Dimension

Low Profile CPU Cooler-SK115LF65AC | G-Alantic Enterprise Co., Ltd.


Input: [SK115LF65AC] EBR [Model No]

Output: Fan Bearing

Low Profile CPU Cooler-SK115LF65AC | G-Alantic Enterprise Co., Ltd.


Input: [SK115LF65AC] 12V [Model No]

Output: Voltage

Low Profile CPU Cooler-SK115LF65AC | G-Alantic Enterprise Co., Ltd.


Input: [SK115LF65AC] 1000~42000RPM [Model No]

Output: Speed

Low Profile CPU Cooler-SK115LF65AC | G-Alantic Enterprise Co., Ltd.


Input: [SK115LF65AC] 21~40 dB(A) [Model No]

Output: Noise

Low Profile CPU Cooler-SK115LF65AC | G-Alantic Enterprise Co., Ltd.


Input: [SK115LF65AC] Aluminum + Copper Core [Model No]

Output: Heat Sink Material

Low Profile CPU Cooler-SK115LF65AC | G-Alantic Enterprise Co., Ltd.


Input: [SK115LF65AC] 65W [Model No]

Output: CPU TDP

Low Profile CPU Cooler-SK115LF65AC | G-Alantic Enterprise Co., Ltd.


Input: [SK115LF65AC] GA6201 、GA6401、GA6602、GA6603、GA677 GA8302、GA8303、GA8304 [Model No]

Output: Apply to

Low Profile CPU Cooler-SK115LF65AC | G-Alantic Enterprise Co., Ltd.


Input: [Company] Baxter [Product Name] CoSeal [Description/Status]

Output: Synthetic, translucent gel for cardiovascular and peripheral vascular surgery applications. Consists of two polyethylene glycol (PEG) polymers that rapidly crosslink with proteins in the tissues, forming a covalent bond. Also mechanically adheres to synthetic graft materials. Intended for adjunctive use to seal areas of leakage.

surgical glue | advanced medical technologies


Input: [Company] Cohera Medical [Product Name] TissuGlu Surgical Adhesive [Description/Status]

Output: Synthetic, resorbable adhesive based on companyÕs proprietary lysine-derived urethane polymer technology. Used for surgeries involving large flap tissue approximation, such as mastectomy and abdominoplasty, to reduce wound drainage and reduce or eliminate the need for wound drains and lower the risk of seroma formation.

surgical glue | advanced medical technologies


Input: [Company] Cohera Medical [Product Name] Sylys Surgical Sealant [Description/Status]

Output: Synthetic sealant designed specifically to help reduce leaks at the anastomosis in gastrointestinal surgery procedures. Used in conjunction with standard closure techniques to protect suture or staple line during first few days of healing.

surgical glue | advanced medical technologies


Input: [Company] CR Bard/Davol [Product Name] Progel (obtained via BardÕs 2012 acquisition of Neomend) [Description/Status]

Output: Hydrogel sealant made of human serum albumin and PEG.

surgical glue | advanced medical technologies


Input: [Company] CryoLife [Product Name] BioGlue [Description/Status]

Output: Bovine serum albumin (BSA)-based surgical adhesive delivered in dual-chamber system.

surgical glue | advanced medical technologies


Input: [Company] CryoLife [Product Name] BioFoam Surgical Matrix [Description/Status]

Output: Dual-action sealant and hemostat. Delivered as liquid and sets into soft foam for difficult to access spaces.

surgical glue | advanced medical technologies


Input: [Company] Endomedix [Product Name] N/A [Description/Status]

Output: In early-stage development with a surgical sealant designed to help control bleeding during brain surgery procedures. Product is a hydrogel comprised of two biocompatible polysaccharides that are simultaneously mixed and sprayed onto the surgical site.

surgical glue | advanced medical technologies


Input: [Company] Gecko Biomedical (France) [Product Name] N/A [Description/Status]

Output: Biodegradable, biocompatible hydrophobic light-activated adhesive made by combining glycerol and sebacic acid. Applied in liquid form and solidifies into leak-proof, flexible seal after a few seconds exposure to UV light.

surgical glue | advanced medical technologies


Input: [Company] Hyperbranch Medical Technology [Product Name] Adherus Dural Sealant [Description/Status]

Output: Hydrogel comprised of two synthetic components: activated PEG and polyethyleneimine. Designed for adjunctive use with standard methods of dural repair during neurosurgery and spinal surgery.

surgical glue | advanced medical technologies


Input: [Company] Integra LifeSciences* [Product Name] DuraSeal [Description/Status]

Output: Absorbable hydrogel dural sealant comprised of synthetic PEG ester solution and trilysine amine solution. Delivered via double barrel system.

surgical glue | advanced medical technologies


Input: [Company] Integra LifeSciences* [Product Name] VascuSeal [Description/Status]

Output: Similar in composition to DuraSeal but intended for use in arterial and venous reconstruction procedures to seal suture lines.

surgical glue | advanced medical technologies


Input: [Company] J&J/Ethicon [Product Name] Omnex Surgical Sealant [Description/Status]

Output: Cyanoacrylate sealant for prevention of leakage along suture lines in vascular reconstruction procedures.

surgical glue | advanced medical technologies


Input: [Company] LifeBond (Israel) [Product Name] LifeSeal/LifePatch Surgical Sealants [Description/Status]

Output: Crosslinked gelatin sealants applied as an adhesive hydrogel matrix. In development for internal wounds and staple-line reinforcement.

surgical glue | advanced medical technologies


Input: [Company] Medical Adhesive Revolution GmbH (Aachen, Germany) [Product Name] N/A [Description/Status]

Output: In development with a high-strength, biodegradable surgical adhesive that can be used instantaneously to stop bleeding within seconds..

surgical glue | advanced medical technologies


Input: [Company] Ocular Therapeutix (formerly I-Therapeutix) [Product Name] ReSure [Description/Status]

Output: Hydrogel sealant designed specifically for use during ophthalmic surgery (such as cataract surgery) as an alternative to sutures.

surgical glue | advanced medical technologies


Input: [Company] Sapheon Inc. (being acquired by Covidien) [Product Name] VenaSeal Sapheon Closure System [Description/Status]

Output: Proprietary catheter-based system that delivers a specially formulated cyanoacrylate medical adhesive to embolize and close the saphenous vein in patients with venous reflux disease. Eliminates the need for surgery, thermal ablation, sedatives, tumescent anesthesia, post-procedure compression stockings, and chemical sclerosants.

surgical glue | advanced medical technologies


Input: [Company] Sealantis Ltd [Product Name] Seal-V [Description/Status]

Output: Protein-free, biodegradable vascular surgery sealant made with Alga-Mimetic Adhesive Technology: mimics algae underwater adherence mechanism.

surgical glue | advanced medical technologies


Input: [Company] Tenaxis Medical (being acquired by The Medicines Company) [Product Name] ArterX Vascular Sealant [Description/Status]

Output: Bioresorbable, gluteraldehyde-based prophylactic synthetic sealant with unique, noninflammatory crosslinking agent that mechanically seals human tissue and artificial grafts in wet or dry field.

surgical glue | advanced medical technologies


Input: [Company] Xcede Technologies Inc. (subsidiary of Dynasil Biomedical Corp.) [Product Name] Xcede Patch [Description/Status]

Output: First product based on platform of ready-to-use, high-strength, fast-acting combination of hemostat/sealant technology initially invented by Dr. Daniel Ericson and acquired by Dynasil in 2011.

surgical glue | advanced medical technologies


Input: [Item] PC00001 [Description] Remington 700 [Type] Right Hand [Finish] Matte [5] Buy Now [Reciever]

Output: Short Action


Input: [Item] PC00002 [Description] Savage Accu-Trigger [Type] Right Hand [Finish] Matte [5] Buy Now [Reciever]

Output: Short Action


Input: [Item] PC00005 [Description] Remington 700 [Type] Right Hand [Finish] Matte [5] Buy Now [Reciever]

Output: Long Action


Input: [Item] PC00006 [Description] Savage [Type] Right Hand [Finish] Matte [5] Buy Now [Reciever]

Output: Long Action


Input: [Item] PC00007 [Description] Winchester® 70 [Type] Right Hand [Finish] Matte [5] Buy Now [Reciever]

Output: Long Action


Input: [Item] PC00008 [Description] Winchester® 70 [Type] Right Hand [Finish] Matte [5] Buy Now [Reciever]

Output: Short Action


Input: [Color Name] Brown [Description]

Output: Resembles a chocolate brownie, and has no orange, red or purple undertone.

Leather Horse Tack- Guide to Leather Colors | Dover Saddlery


Input: [Color Name] Chestnut [Description]

Output: A brown color that borders between light and medium color depth and has strong orangey-red undertones. Very similar to the color of a chestnut horse in the sun.

Leather Horse Tack- Guide to Leather Colors | Dover Saddlery


Input: [Color Name] Chocolate [Description]

Output: Neither very dark nor very light, this is a rich brown color similar to that of a premium chocolate bar. It is very similar in appearance to Medium Brown.

Leather Horse Tack- Guide to Leather Colors | Dover Saddlery


Input: [Color Name] Cognac [Description]

Output: Aptly named for its resemblance to cognac liquor, this is a medium brown color with subtle auburn undertones.

Leather Horse Tack- Guide to Leather Colors | Dover Saddlery


Input: [Color Name] Dark Brown [Description]

Output: Resembles the color of a moist, dark chocolate brownie, and has a subtle purple undertone. Not as dark as Ebony, but very dark.

Leather Horse Tack- Guide to Leather Colors | Dover Saddlery


Input: [Color Name] Ebony [Description]

Output: An extremely dark brown.

Leather Horse Tack- Guide to Leather Colors | Dover Saddlery


Input: [Color Name] Havana [Description]

Output: A deep brown that does not have any red, orange or purple undertones. Resembles the color of a dark chocolate bar.

Leather Horse Tack- Guide to Leather Colors | Dover Saddlery


Input: [Color Name] Hazelnut [Description]

Output: A light brown color with orange undertones as can be seen on the shell of a hazelnut.

Leather Horse Tack- Guide to Leather Colors | Dover Saddlery


Input: [Color Name] Medium Brown [Description]

Output: Neither very deep nor very light, this is a rich brown color similar to that of a premium milk chocolate bar. This color is very similar to Chocolate.

Leather Horse Tack- Guide to Leather Colors | Dover Saddlery


Input: [Color Name] Newmarket [Description]

Output: The lightest of brown leather colors, this is a light brown with yellow, orange or red undertones.

Leather Horse Tack- Guide to Leather Colors | Dover Saddlery


Input: [Color Name] Oakbark [Description]

Output: A soft, medium brown color with dark yellow or red undertones; it closely resembles the bark of an oak tree.

Leather Horse Tack- Guide to Leather Colors | Dover Saddlery


Input: [Color Name] Tobacco [Description]

Output: A light brown with an orange hue. It takes its name from the color of dried tobacco leaves.

Leather Horse Tack- Guide to Leather Colors | Dover Saddlery


Input: [Color Name] Walnut [Description]

Output: A dark brown with no undertones of orange, red or purple. (Darker than a walnut shell.)

Leather Horse Tack- Guide to Leather Colors | Dover Saddlery


Input: [Latin name] Achillea millefolium subsp. millefolium [Common name] Yarrow [Naturalisation notes] Cultivated ornamental [Invasiveness] Naturalised

Output: Scarce

FI Conservation - Vascular plant checklists


Input: [Latin name] Agrostis capillaris [Common name] Common Bent [Naturalisation notes] Cultivated pasture & lawn [Invasiveness] Naturalised - spreading

Output: Scarce

FI Conservation - Vascular plant checklists


Input: [Latin name] Agrostis stolonifera [Common name] Creeping Bent [Naturalisation notes] Cultivated pasture & lawn [Invasiveness] Naturalised

Output: Occasional

FI Conservation - Vascular plant checklists


Input: [Latin name] Aira caryophyllea [Common name] Silver Hair-grass [Naturalisation notes] Not cultivated [Invasiveness] Naturalised

Output: Scarce

FI Conservation - Vascular plant checklists


Input: [Latin name] Aira praecox [Common name] Early Hair-grass [Naturalisation notes] Not cultivated [Invasiveness] Naturalised

Output: Frequent

FI Conservation - Vascular plant checklists


Input: [Latin name] Allium schoenoprasum [Common name] Chives [Naturalisation notes] Cultivated herb [Invasiveness] Naturalised - anthropogenic

Output: Rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Allium triquetrum [Common name] Three-cornered Garlic [Naturalisation notes] Cultivated ornamental [Invasiveness] Naturalised - anthropogenic

Output: Rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Alopecurus geniculatus [Common name] Marsh Foxtail [Naturalisation notes] Cultivated for pasture [Invasiveness] Naturalised

Output: Rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Ammophila arenaria [Common name] Marram [Naturalisation notes] Erosion control [Invasiveness] Naturalised - spreading

Output: Occasional

FI Conservation - Vascular plant checklists


Input: [Latin name] Anthemis punctata subsp. cupaniana [Common name] Sicilian Chamomile [Naturalisation notes] Cultivated ornamental [Invasiveness] Naturalised

Output: Very rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Anthoxanthum odoratum [Common name] Sweet Vernal-grass [Naturalisation notes] Cultivated for pasture [Invasiveness] Naturalised

Output: Occasional

FI Conservation - Vascular plant checklists


Input: [Latin name] Anthriscus sylvestris [Common name] Cow Parsley [Naturalisation notes] Not cultivated [Invasiveness] Naturalised

Output: Very rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Aphanes arvensis [Common name] Parsley-piert [Naturalisation notes] Not cultivated [Invasiveness] Naturalised

Output: Rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Armoracia rusticana [Common name] Horseradish [Naturalisation notes] Cultivated herb [Invasiveness] Naturalised

Output: Very rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Arrhenatherum elatius [Common name] False Oat-grass [Naturalisation notes] Not cultivated [Invasiveness] Unknown

Output: Very rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Asplenium scolopendrium [Common name] Hart's-tongue Fern [Naturalisation notes] Unknown [Invasiveness] Unknown

Output: Very rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Atriplex patula [Common name] Common Orache [Naturalisation notes] Not cultivated [Invasiveness] Naturalised

Output: Rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Atriplex prostrata [Common name] Spear-leaved Orache [Naturalisation notes] Not cultivated [Invasiveness] Casual

Output: Very rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Avena sativa [Common name] Oat [Naturalisation notes] Cultivated for fodder [Invasiveness] Naturalised

Output: Rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Bellis perennis [Common name] Daisy [Naturalisation notes] Cultivated ornamental [Invasiveness] Naturalised

Output: Frequent

FI Conservation - Vascular plant checklists


Input: [Latin name] Berberis microphylla [Common name] Calafate [Naturalisation notes] Cultivated ornamental [Invasiveness] Naturalised

Output: Rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Brassica oleracea [Common name] Cabbage [Naturalisation notes] Cultivated vegetable [Invasiveness] Naturalised

Output: Very rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Brassica rapa subsp. rapa [Common name] Turnip [Naturalisation notes] Cultivated vegetable & fodder [Invasiveness] Naturalised

Output: Very rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Bromus catharticus [Common name] Rescue Brome [Naturalisation notes] Not cultivated [Invasiveness] Unknown

Output: Very rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Bromus condensatus [Common name] Upright Brome [Naturalisation notes] Not cultivated [Invasiveness] Unknown

Output: Very rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Bromus hordeaceus subsp. hordeaceus [Common name] Soft Brome [Naturalisation notes] Not cultivated [Invasiveness] Naturalised - anthropogenic

Output: Rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Bromus sterilis [Common name] Barren Brome [Naturalisation notes] Not cultivated [Invasiveness] Naturalised

Output: Very rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Calluna vulgaris [Common name] Heather [Naturalisation notes] Cultivated ornamental [Invasiveness] Naturalised

Output: Rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Capsella bursa-pastoris [Common name] Shepherd's-purse [Naturalisation notes] Not cultivated [Invasiveness] Naturalised

Output: Occasional

FI Conservation - Vascular plant checklists


Input: [Latin name] Cardamine hirsuta [Common name] Hairy Bitter-cress [Naturalisation notes] Not cultivated [Invasiveness] Naturalised

Output: Very rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Carex flacca [Common name] Glaucous Sedge [Naturalisation notes] Not cultivated [Invasiveness] Naturalised

Output: Very rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Castanea sativa [Common name] Sweet Chestnut [Naturalisation notes] Ornamental & windbreak [Invasiveness] Persisting (Taxa)

Output: Very rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Cerastium fontanum subsp. vulgare [Common name] Common Mouse-ear [Naturalisation notes] Not cultivated [Invasiveness] Naturalised

Output: Frequent

FI Conservation - Vascular plant checklists


Input: [Latin name] Cerastium glomeratum [Common name] Sticky Mouse-ear [Naturalisation notes] Not cultivated [Invasiveness] Naturalised - anthropogenic

Output: Very rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Cirsium arvense var. arvense [Common name] Creeping Thistle [Naturalisation notes] Not cultivated [Invasiveness] Naturalised - anthropogenic

Output: Rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Cirsium vulgare [Common name] Spear Thistle [Naturalisation notes] Not cultivated [Invasiveness] Naturalised - anthropogenic

Output: Rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Claytonia perfoliata [Common name] Spring beauty [Naturalisation notes] Not cultivated [Invasiveness] Naturalised - anthropogenic

Output: Very rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Cochlearia officinalis subsp. officinalis [Common name] English Scurvygrass [Naturalisation notes] Not cultivated [Invasiveness] Naturalised

Output: Rare

FI Conservation - Vascular plant checklists


Input: [Latin name] Conium maculatum [Common name] Hemlock [Naturalisation notes] Not cultivated [Invasiveness] Naturalised - anthropogenic

Output: Very rare

FI Conservation - Vascular plant checklists